Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study

ObjectivesTo evaluate the efficacy of biosimilar (BIO) pegfilgrastim (PEG) in lymphoma patients after autologous stem cell transplantation (ASCT).Methods86 consecutive lymphoma patients who received BIO/PEG after ASCT were assessed. The primary endpoints of this study were the incidence of febrile n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers in hematology 2024-07, Vol.3
Hauptverfasser:	Loteta, Barbara, Pitino, Annalisa, Pitea, Martina, Alati, Caterina, Tripepi, Giovanni, Mico', Maria Caterina, Pellicano', Maria, Cogliandro, Francesca, Porto, Gaetana, Policastro, Giorgia, Utano, Giovanna, Delfino, Ilaria Maria, Sgarlata, Annalisa, Scopelliti, Anna, Idato, Aurora, Laenza, Giovanni, Altomonte, Maria, D'Arrigo, Graziella, Gori, Mercedes, Martino, Massimo
Format:	Artikel
Sprache:	eng
Schlagworte:	autologous stem cell transplantation BIO-PEG biosimilar pegfilgrastim chemotherapy lymphoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ObjectivesTo evaluate the efficacy of biosimilar (BIO) pegfilgrastim (PEG) in lymphoma patients after autologous stem cell transplantation (ASCT).Methods86 consecutive lymphoma patients who received BIO/PEG after ASCT were assessed. The primary endpoints of this study were the incidence of febrile neutropenia (FN) and time to neutrophil engraftment.ResultsMost patients were males (67.4%) with a median age of 48 years. FN occurred in 66 patients (76.7%), and most of the fever was grade 1-2. The median time to neutrophil engraftment was 9 days. The incidence of FN differs based on lymphoma type (p-value
ISSN:	2813-3935 2813-3935
DOI:	10.3389/frhem.2024.1441070